Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05735769
Other study ID # VaxITLB-19 2021
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 1, 2021
Est. completion date September 15, 2021

Study information

Verified date February 2023
Source University of Bari
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

In 2021 and following the COVID-19 (corona virus disease 2019) pandemic, different vaccines were initially authorized in Italy and Lebanon. Notably, vaccine side effects were poorly recorded. Thus, the investigator performed a survey study to monitor COVID-19 vaccine side effects among Italian and Lebanese citizens according to gender and age through a web-based questionnaire in Italian and Arabic languages including 21 items by "Google Form", investigating 13 symptoms, and employing social-media platforms


Description:

The COVID-19 pandemic has presented a real challenge to the public health system worldwide since the year 2019, spreading to more than 200 countries and regions worldwide.The emergence and rapid spread of COVID-19 were caused by the coronavirus SARS-CoV-2. Worldwide, the use of COVID-19 vaccines was initially authorized for emergency use and the side effects were not stated clearly. Common side effects were expected but specific side effects linked with COVID-19 vaccines remained uncertain. In this context, survey studies are needed for a comprehensive evaluation of the relationships between vaccine administration, related undesired effects and vaccine safety. This study represents the first survey following early COVID-19 vaccines administration in two geographic areas, comparatively considering possible differences due to gender and age. A web-based survey was conducted on a cohort of 1975 Italian and 822 Lebanese people who received at least one dose of COVID-19 vaccine. The study was conducted between March and July 2021 on a voluntary basis, and by a tailored anonymous web-based questionnaire. The protocol was approved by the local Ethics Committee, University of Bari 'Aldo Moro' (study number 6752, protocol number 0031044). A specific questionnaire was designed in English and translated into Italian and Arabic. It contains 21 items including demographic data, the history of vaccine administration before COVID-19, the administration of the first and second dose of COVID-19 vaccine, and possible adverse effects. The survey link was shared by a "Google Form" employing social-media platforms or by personal interview. The questionnaire explored the presence of 13 possible symptoms appearing following the administration of the first and second dose of COVID-19 vaccine: pain at the injection site, redness at the injection site, swelling at the injection site, induration at the injection site, allergic-urticarial reaction, anaphylaxis, fever (>37 °C), diarrhea, vomiting, asthenia/fatigue, muscle pain, rash, sleepiness/insomnia, irritability/nervousness, headache, lymphadenopathy. The presence and intensity of symptoms were assessed semi-quantitatively by a Visual Analogue Scale (VAS). Besides symptoms, the following aspects were also evaluated: need of drug intake, consultation of a doctor, emergency admission to hospital, and possible hospitalization.


Recruitment information / eligibility

Status Completed
Enrollment 2797
Est. completion date September 15, 2021
Est. primary completion date July 30, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - Anti-COVID-19 vaccine Exclusion Criteria: - Subjects who living outside Italy or Lebanon

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Italy Department of Biomedical Sciences and Human Oncology - Clinica medica "A. Murri" Bari BA

Sponsors (2)

Lead Sponsor Collaborator
University of Bari Lebanese University

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Symptoms post anti-COVID-19 vaccine The questionnaire explored the presence of 13 possible symptoms appearing following the administration of the first and second dose of COVID-19 vaccine: pain at the injection site, redness at the injection site, swelling at the injection site, induration at the injection site, allergic-urticarial reaction, anaphylaxis, fever (>37 °C), diarrhea, vomiting, asthenia/fatigue, muscle pain, rash, sleepiness/insomnia, irritability/nervousness, headache, and lymphadenopathy 5 months
Secondary Severity score post-vaccine anti-COVID-19 The severity score of symptoms was calculated as follows: [? (symptom * duration in hrs * intensity in VAS (visual analog score)] + use of antipyretic drugs (1point) + use of other analgesic drugs (1 point) + recourse to a doctor (1 point) + recourse to emergency room without admission to the ward (1 point) + admission to hospital ward (1 point). The range of the severity score was from 0 to 216 after first dose or second dose 5 months
See also
  Status Clinical Trial Phase
Completed NCT03966391 - Effectiveness of CARD for Improving School-Based Immunizations N/A
Completed NCT04530357 - Reactogenicity, Safety and Immunogenicity of QazCovid-in® COVID-19 Vaccine Phase 1/Phase 2
Terminated NCT03966300 - Improving the School Vaccination Experience: What CARDs Are You Going to Play? N/A
Active, not recruiting NCT06286488 - Effectiveness and Tolerability of Influenza Vaccine in Patients at Risk for Severe and Complicated Influenza Phase 4
Recruiting NCT05546502 - Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Children Phase 3
Active, not recruiting NCT05483725 - Immunological Safety and Effectiveness of the First Booster Dose of mRNA Vaccines Against COVID-19 in Kidney Transplant Recipients.
Completed NCT03600428 - Safety of LAIV4 in Children With Asthma Phase 4
Completed NCT03400878 - Comparing Morbidity and Mortality Effects of Two Different Strains of BCG Phase 4
Completed NCT05116748 - COVID19 Vaccine in SOT Adult Recipients
Not yet recruiting NCT05171946 - Phase-I Study to Evaluate the Safety and Immunogenicity of a Prophylactic pDNA Vaccine Candidate Against COVID-19 in Healthy Adults Phase 1
Recruiting NCT05128721 - Evaluation of Inactivated Vaccine in Healthy Adults Against Coronavirus Disease of 2019 (COVID-19) Phase 1
Withdrawn NCT04894682 - Safety and Long-term Effects of COVID-19 Vaccines in Patients With Pulmonary Tumor
Not yet recruiting NCT05387252 - Glucoside- and Rutinoside-rich Crude Material for Relieving Side Effects of COVID-19 Vaccines N/A
Active, not recruiting NCT04801667 - Evaluate the Impact, Safety, Tolerability and Immunogenicity of the Coronavac Vaccine in Kidney Transplant Recipients Phase 4
Not yet recruiting NCT05283902 - Effectiveness, Immunogenicity and Safety of the Second Booster Dose of the Vaccine Against COVID-19 in the Elderly
Recruiting NCT05095844 - National Vaccine Adverse Event Reporting Survey and Etiology
Recruiting NCT05315856 - Reactogenicity, Immunogenicity and Inflammatory Response by New COVID-19 Vaccine Platforms
Recruiting NCT05898464 - Immunogenicity and Safety of Recombinant Zoster Vaccine in People Living With HIV Phase 4
Recruiting NCT05212792 - Genomics and COVID-19 Vaccine Adverse Events
Recruiting NCT05258708 - COVID-19 Vaccine Reactogenicity and Immunogenicity